1 / 19

Gleevec® (imatinib mesylate)

Gleevec® (imatinib mesylate). Advancing the Treatment of Ph+ Chronic Myeloid Leukemia (CML). Doug Brutlag Professor Emeritus of Biochemistry and Medicine brutlag@stanford.edu. CML: a Progressive and Fatal Disease. CML: Linked to a Single Molecular Abnormality.

jabari
Télécharger la présentation

Gleevec® (imatinib mesylate)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Gleevec®(imatinib mesylate) Advancing the Treatment of Ph+ Chronic Myeloid Leukemia (CML) Doug Brutlag Professor Emeritus of Biochemistry and Medicine brutlag@stanford.edu

  2. CML: a Progressive and Fatal Disease

  3. CML: Linked to a Single Molecular Abnormality

  4. Gleevec® Targets the Cause of CML

  5. Inhibition of Cellular Proliferation by Gleevechttp://www.biocarta.com/pathfiles/h_gleevecpathway.asp

  6. CML: Its Cause and Management

  7. Gleevec®: Pharmacokinetics

  8. Phase I Study: Gleevec® Achieves Hematologic and Cytogenetic Responses

  9. Phase II Results: Highest Response Rates in Chronic Phase

  10. Higher Dose: Longer Time to Disease Progression

  11. IRIS Study: Reevaluating First-Line CML Therapy

  12. IRIS: The Largest Phase III CML Study to Date

  13. Longer Time to Progression With Gleevec®

  14. Higher Cytogenetic Response Rates With Gleevec®

  15. Early Responses in More Patients With Gleevec®

  16. More Patients Remain on Gleevec® Therapy

  17. Most Non-Hematologic Adverse Events Less Common With Gleevec®

  18. Fewer Hematologic Adverse Events With Gleevec®

  19. Massive Protein Kinase Database • Abbott Labs Publishes Massive Protein Kinase Dataset, New Statistical Method to Analyze Kinome • March 11, 2011 • By Adam Bonislawski • Scientists from Abbott Laboratories' pharmaceutical-discovery division have released kinomics screening data about how 3,800 different inhibitors affect 172 protein kinases. • In a study published last month in the online edition of Nature Chemical Biology, the researchers showed how they tried to group these kinases based on both sequence and pharmacological relationships and by their interactions with various inhibitor chemoty

More Related